全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

The Pharmacogenomics of Anti-Hypertensive Therapy

DOI: 10.3390/ph3061779

Keywords: hypertension, pharmacogenetics, pharmacogenomics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, antihypertensive, calcium channel blockers, thiazide diuretics

Full-Text   Cite this paper   Add to My Lib

Abstract:

Hypertension is a major public health problem, but measures to reduce blood pressure and thus cardiovascular risk are complicated by the high prevalence of treatment resistance, despite the availability of multiple drugs. Drug side-effects contribute considerably to suboptimal blood pressure control. Clinicians must often rely on empirical methods to match patients with effective drug treatment. Hypertension pharmacogenomics seeks to find genetic predictors of response to drugs that lower blood pressure and to translate this knowledge into clinical practice. In this review we summarise the current status of hypertension pharmacogenetics from monogenic hypertension to essential hypertension and discuss the issues that need to be considered in a hypertension pharmacogenomic study.

 References

[1]  Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet？2002, 360(9349), 1903–1913. 12493255
[2]  Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet？2005, 365(9455), 217–223. 15652604
[3]  Ezzati, M.; Lopez, A.D.; Rodgers, A.; Vander, H.S.; Murray, C.J. Selected major risk factors and global and regional burden of disease. Lancet？2002, 360(9343), 1347–1360. 12423980
[4]  Hajjar, I.; Kotchen, T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA？2003, 290(2), 199–206, doi:10.1001/jama.290.2.199. 12851274
[5]  Lloyd-Jones, D.M.; Evans, J.C.; Larson, M.G.; O'Donnell, C.J.; Roccella, E.J.; Levy, D. Differential control of systolic and diastolic blood pressure : Factors associated with lack of blood pressure control in the community. Hypertension？2000, 36(4), 594–599. 11040241
[6]  Thoenes, M.; Neuberger, H.R.; Volpe, M.; Khan, B.V.; Kirch, W.; Bohm, M. Antihypertensive drug therapy and blood pressure control in men and women: An international perspective. J. Hum. Hypertens.？2010, 24(5), 336–344, doi:10.1038/jhh.2009.76. 19798089
[7]  Cushman, W.C.; Ford, C.E.; Cutler, J.A.; Margolis, K.L.; Davis, B.R.; Grimm, R.H.; Black, H.R.; Hamilton, B.P.; Holland, J.; Nwachuku, C.; Papademetriou, V.; Probstfield, J.; Wright, J.T., Jr.; Alderman, M.H.; Weiss, R.J.; Piller, L.; Bettencourt, J.; Walsh, S.M. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens.？2002, 4(6), 393–404, doi:10.1111/j.1524-6175.2002.02045.x.
[8]  Canzanello, V.J.; Baranco-Pryor, E.; Rahbari-Oskoui, F.; Schwartz, G.L.; Boerwinkle, E.; Turner, S.T.; Chapman, A.B. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am. J. Hypertens.？2008, 21(1), 61–66, doi:10.1038/ajh.2007.24. 18091745
[9]  Blaufox, M.D.; Lee, H.B.; Davis, B.; Oberman, A.; Wassertheil-Smoller, S.; Langford, H. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA？1992, 267(9), 1221–1225. 1538559
[10]  Calhoun, D.A.; Jones, D.; Textor, S.; Goff, D.C.; Murphy, T.P.; Toto, R.D.; White, A.; Cushman, W.C.; White, W.; Sica, D.; Ferdinand, K.; Giles, T.D.; Falkner, B.; Carey, R.M. Resistant hypertension: diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation？2008, 117(25), e510–e526. 18574054
[11]  Chapman, A.B.; Schwartz, G.L.; Boerwinkle, E.; Turner, S.T. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int.？2002, 61(3), 1047–1055, doi:10.1046/j.1523-1755.2002.00200.x. 11849460
[12]  Brewster, L.M.; van Montfrans, G.A.; Kleijnen, J. Systematic review: Antihypertensive drug therapy in black patients. Ann. Intern. Med.？2004, 141(8), 614–627, doi:10.7326/0003-4819-141-8-200410190-00009. 15492341
[13]  Johnson, J.A. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation？2008, 118(13), 1383–1393, doi:10.1161/CIRCULATIONAHA.107.704023. 18809808
[14]  Brown, M.J.; Cruickshank, J.K.; Dominiczak, A.F.; MacGregor, G.A.; Poulter, N.R.; Russell, G.I.; Thom, S.; Williams, B. Better blood pressure control: How to combine drugs. J. Hum. Hypertens.？2003, 17(2), 81–86. 12574784
[15]  Blumenfeld, J.D.; Laragh, J.H. Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension. Am. J. Hypertens.？1998, 11(7), 894–896, doi:10.1016/S0895-7061(98)00080-6. 9683058
[16]  Laragh, J.H. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int.？1993, 44(5), 1163–1175, doi:10.1038/ki.1993.363. 8264150
[17]  Buhler, F.R.; Bolli, P.; Kiowski, W.; Erne, P.; Hulthen, U.L.; Block, L.H. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am. J. Med.？1984, 77(2A), 36–42. 6148011
[18]  Laragh, J.H.; Resnick, L.M. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int.？1988, 25, S162–S174.
[19]  Williams, B.; Poulter, N.R.; Brown, M.J.; Davis, M.; McInnes, G.T.; Potter, J.F.; Sever, P.S.; Thom, S.M. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ？2004, 328(7440), 634–640. 15016698
[20]  Padmanabhan, S.; Delles, C.; Dominiczak, A.F. Genetic factors in hypertension. Arch. Med. Sci.？2009, 5(2A), S212–S219.
[21]  Lifton, R.P.; Dluhy, R.G.; Powers, M.; Rich, G.M.; Gutkin, M.; Fallo, F.; Gill, J.R., Jr.; Feld, L.; Ganguly, A.; Laidlaw, J.C. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat. Genet.？1992, 2(1), 66–74, doi:10.1038/ng0992-66. 1303253
[22]  Geller, D.S.; Farhi, A.; Pinkerton, N.; Fradley, M.; Moritz, M.; Spitzer, A.; Meinke, G.; Tsai, F.T.; Sigler, P.B.; Lifton, R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science？2000, 289(5476), 119–123. 10884226
[23]  Shimkets, R.A.; Warnock, D.G.; Bositis, C.M.; Nelson-Williams, C.; Hansson, J.H.; Schambelan, M.; Gill, J.R., Jr.; Ulick, S.; Milora, R.V.; Findling, J.W. Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell？1994, 79(3), 407–414, doi:10.1016/0092-8674(94)90250-X. 7954808
[24]  Hansson, J.H.; Nelson-Williams, C.; Suzuki, H.; Schild, L.; Shimkets, R.; Lu, Y.; Canessa, C.; Iwasaki, T.; Rossier, B.; Lifton, R.P. Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle syndrome. Nat. Genet.？1995, 11(1), 76–82, doi:10.1038/ng0995-76. 7550319
[25]  Wilson, F.H.; Disse-Nicodeme, S.; Choate, K.A.; Ishikawa, K.; Nelson-Williams, C.; Desitter, I.; Gunel, M.; Milford, D.V.; Lipkin, G.W.; Achard, J.M.; Feely, M.P.; Dussol, B.; Berland, Y.; Unwin, R.J.; Mayan, H.; Simon, D.B.; Farfel, Z.; Jeunemaitre, X.; Lifton, R.P. Human hypertension caused by mutations in WNK kinases. Science？2001, 293(5532), 1107–1112. 11498583
[26]  Carretero, O.A.; Oparil, S. Essential hypertension. Part I: Definition and etiology. ？2000, 101(3), 329–335. 10645931
[27]  Luft, F.C. Twins in cardiovascular genetic research. Hypertension？2001, 37(2), 350–356. 11230299
[28]  Mongeau, J.G.; Biron, P.; Sing, C.F. The influence of genetics and household environment upon the variability of normal blood pressure: The Montreal Adoption Survey. Clin. Exp. Hypertens.？1986, 8(4&5), 653–660, doi:10.3109/10641968609046581.
[29]  Cowley, A.W., Jr. The genetic dissection of essential hypertension. Nat. Rev. Genet.？2006, 7(11), 829–840, doi:10.1038/nrg1967. 17033627
[30]  Gu, C.C.; Hunt, S.C.; Kardia, S.; Turner, S.T.; Chakravarti, A.; Schork, N.; Olshen, R.; Curb, D.; Jaquish, C.; Boerwinkle, E.; Rao, D.C. An investigation of genome-wide associations of hypertension with microsatellite markers in the family blood pressure program (FBPP). Hum. Genet.？2007, 121(5), 577–590, doi:10.1007/s00439-007-0349-8. 17372766
[31]  Caulfield, M.; Munroe, P.; Pembroke, J.; Samani, N.; Dominiczak, A.; Brown, M.; Benjamin, N.; Webster, J.; Ratcliffe, P.; O'Shea, S.; Papp, J.; Taylor, E.; Dobson, R.; Knight, J.; Newhouse, S.; Hooper, J.; Lee, W.; Brain, N.; Clayton, D.; Lathrop, G.M.; Farrall, M.; Connell, J. Genome-wide mapping of human loci for essential hypertension. Lancet？2003, 361(9375), 2118–2123. 12826435
[32]  Padmanabhan, S.; Wallace, C.; Munroe, P.B.; Dobson, R.; Brown, M.; Samani, N.; Clayton, D.; Farrall, M.; Webster, J.; Lathrop, M.; Caulfield, M.; Dominiczak, A.F.; Connell, J.M. Chromosome 2p shows significant linkage to antihypertensive response in the British Genetics of Hypertension Study. Hypertension？2006, 47(3), 603–608, doi:10.1161/01.HYP.0000197947.62601.9d. 16391175
[33]  Barkley, R.A.; Chakravarti, A.; Cooper, R.S.; Ellison, R.C.; Hunt, S.C.; Province, M.A.; Turner, S.T.; Weder, A.B.; Boerwinkle, E. Positional identification of hypertension susceptibility genes on chromosome 2. Hypertension？2004, 43(2), 477–482, doi:10.1161/01.HYP.0000111585.76299.f7. 14732741
[34]  Padmanabhan, S.; Melander, O.; Hastie, C.; Menni, C.; Delles, C.; Connell, J.M.; Dominiczak, A.F. Hypertension and genome-wide association studies: Combining high fidelity phenotyping and hypercontrols. J. Hypertens.？2008, 26(7), 1275–1281, doi:10.1097/HJH.0b013e3282ff634f. 18550997
[35]  Arnett, D.K.; Davis, B.R.; Ford, C.E.; Boerwinkle, E.; Leiendecker-Foster, C.; Miller, M.B.; Black, H.; Eckfeldt, J.H. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation？2005, 111(25), 3374–3383. 15967849
[36]  Brunner, M.; Cooper-DeHoff, R.M.; Gong, Y.; Karnes, J.H.; Langaee, T.Y.; Pepine, C.J.; Johnson, J.A. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am. J. Cardiol.？2007, 99(11), 1549–1554, doi:10.1016/j.amjcard.2007.01.029. 17531579
[37]  Turner, S.T.; Schwartz, G.L.; Chapman, A.B.; Boerwinkle, E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension？2005, 46(4), 758–765, doi:10.1161/01.HYP.0000186240.81996.57. 16172412
[38]  Arnett, D.K.; Claas, S.A.; Lynch, A.I. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr. Opin. Cardiol.？2009, 24(4), 333–339, doi:10.1097/HCO.0b013e32832c58ba. 19509486
[39]  Pacanowski, M.A.; Gong, Y.; Cooper-DeHoff, R.M.; Schork, N.J.; Shriver, M.D.; Langaee, T.Y.; Pepine, C.J.; Johnson, J.A. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther.？2008, 84(6), 715–721, doi:10.1038/clpt.2008.139. 18615004
[40]  Lemaitre, R.N.; Heckbert, S.R.; Sotoodehnia, N.; Bis, J.C.; Smith, N.L.; Marciante, K.D.; Hindorff, L.A.; Lange, L.A.; Lumley, T.S.; Rice, K.M.; Wiggins, K.L.; Psaty, B.M. beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am. J. Hypertens.？2008, 21(3), 290–296. 18219297
[41]  Johnson, J.A.; Zineh, I.; Puckett, B.J.; McGorray, S.P.; Yarandi, H.N.; Pauly, D.F. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther.？2003, 74(1), 44–52, doi:10.1016/S0009-9236(03)00068-7. 12844134
[42]  Liu, J.; Liu, Z.Q.; Yu, B.N.; Xu, F.H.; Mo, W.; Zhou, G.; Liu, Y.Z.; Li, Q.; Zhou, H.H. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther.？2006, 80(1), 23–32, doi:10.1016/j.clpt.2006.03.004. 16815314
[43]  Psaty, B.M.; Smith, N.L.; Heckbert, S.R.; Vos, H.L.; Lemaitre, R.N.; Reiner, A.P.; Siscovick, D.S.; Bis, J.; Lumley, T.; Longstreth, W.T., Jr.; Rosendaal, F.R. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA？2002, 287(13), 1680–1689. 11926892
[44]  Davis, B.R.; Arnett, D.K.; Boerwinkle, E.; Ford, C.E.; Leiendecker-Foster, C.; Miller, M.B.; Black, H.; Eckfeldt, J.H. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J.？2007, 7(2), 112–122, doi:10.1038/sj.tpj.6500395. 16702981
[45]  Gerhard, T.; Gong, Y.; Beitelshees, A.L.; Mao, X.; Lobmeyer, M.T.; Cooper-DeHoff, R.M.; Langaee, T.Y.; Schork, N.J.; Shriver, M.D.; Pepine, C.J.; Johnson, J.A. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am. Heart J.？2008, 156(2), 397–404, doi:10.1016/j.ahj.2008.03.007. 18657677
[46]  Manunta, P.; Lavery, G.; Lanzani, C.; Braund, P.S.; Simonini, M.; Bodycote, C.; Zagato, L.; Delli, C.S.; Tantardini, C.; Brioni, E.; Bianchi, G.; Samani, N.J. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension？2008, 52(2), 366–372, doi:10.1161/HYPERTENSIONAHA.108.113977. 18591455
[47]  De Buyzere, M. Selective genetic advantages for users of thiazide diuretics. Is there a case for the 460Trp variant of alpha-adducin? J. Hypertens.？2009, 27(1), 24–27, doi:10.1097/HJH.0b013e32831cf01b. 19050446
[48]  Kelley-Hedgepeth, A.; Peter, I.; Kip, K.; Montefusco, M.; Kogan, S.; Cox, D.; Ordovas, J.; Levy, D.; Reis, S.; Mendelsohn, M.; Housman, D.; Huggins, G. The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. J. Hum. Hypertens.？2008, 22(7), 512–515, doi:10.1038/jhh.2008.23. 18418400
[49]  Beitelshees, A.L.; Gong, Y.; Wang, D.; Schork, N.J.; Cooper-DeHoff, R.M.; Langaee, T.Y.; Shriver, M.D.; Sadee, W.; Knot, H.J.; Pepine, C.J.; Johnson, J.A. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet. Genomics？2007, 17(9), 719–729, doi:10.1097/FPC.0b013e32810f2e3c. 17700361
[50]  Turner, S.T.; Bailey, K.R.; Fridley, B.L.; Chapman, A.B.; Schwartz, G.L.; Chai, H.S.; Sicotte, H.; Kocher, J.P.; Rodin, A.S.; Boerwinkle, E. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension？2008, 52(2), 359–365, doi:10.1161/HYPERTENSIONAHA.107.104273. 18591461
[51]  Kurland, L.; Lind, L.; Melhus, H. Using genotyping to predict responses to anti-hypertensive treatment. Trends Pharmacol. Sci.？2005, 26(9), 443–447. 16055200
[52]  Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy—A genomewide study. N. Engl. J. Med.？2008, 359(8), 789–799. 18650507
[53]  Eichler, E.E.; Flint, J.; Gibson, G.; Kong, A.; Leal, S.M.; Moore, J.H.; Nadeau, J.H. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet？2010, 11(6), 446–450, doi:10.1038/nrg2809. 20479774
[54]  Cantor, R.M.; Lange, K.; Sinsheimer, J.S. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am. J. Hum. Genet？2010, 86(1), 6–22, doi:10.1016/j.ajhg.2009.11.017. 20074509
[55]  Chanock, S.J.; Manolio, T.; Boehnke, M.; Boerwinkle, E.; Hunter, D.J.; Thomas, G.; Hirschhorn, J.N.; Abecasis, G.; Altshuler, D.; Bailey-Wilson, J.E.; Brooks, L.D.; Cardon, L.R.; Daly, M.; Donnelly, P.; Fraumeni, J.F., Jr.; Freimer, N.B.; Gerhard, D.S.; Gunter, C.; Guttmacher, A.E.; Guyer, M.S.; Harris, E.L.; Hoh, J.; Hoover, R.; Kong, C.A.; Merikangas, K.R.; Morton, C.C.; Palmer, L.J.; Phimister, E.G.; Rice, J.P.; Roberts, J.; Rotimi, C.; Tucker, M.A.; Vogan, K.J.; Wacholder, S.; Wijsman, E.M.; Winn, D.M.; Collins, F.S. Replicating genotype-phenotype associations. Nature？2007, 447(7145), 655–660. 17554299
[56]  Padmanabhan, S.; Menni, C.; Lee, W.K.; Laing, S.; Brambilla, P.; Sega, R.; Perego, R.; Grassi, G.; Cesana, G.; Delles, C.; Mancia, G.; Dominiczak, A.F. The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. J. Hypertens.？2010, 28(3), 465–477. 20032787
[57]  Pickering, T.G.; Hall, J.E.; Appel, L.J.; Falkner, B.E.; Graves, J.; Hill, M.N.; Jones, D.W.; Kurtz, T.; Sheps, S.G.; Roccella, E.J. Recommendations for blood pressure measurement in humans and experimental animals: part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation？2005, 111(5), 697–716. 15699287
[58]  Trazzi, S.; Mutti, E.; Frattola, A.; Imholz, B.; Parati, G.; Mancia, G. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J. Hypertens.？1991, 9(2), 115–119. 1849525
[59]  Mancia, G.; Parati, G.; Pomidossi, G.; Grassi, G.; Casadei, R.; Zanchetti, A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension？1987, 9(2), 209–215. 3818018
[60]  Andersen, U.O.; Henriksen, J.H.; Jensen, G. Sources of measurement variation in blood pressure in large-scale epidemiological surveys with follow-up. Blood Press？2002, 11(6), 357–365, doi:10.1080/080370502321095320. 12523679
[61]  Dasgupta, K.; O'Loughlin, J.; Chen, S.; Karp, I.; Paradis, G.; Tremblay, J.; Hamet, P.; Pilote, L. Emergence of sex differences in prevalence of high systolic blood pressure: Analysis of a longitudinal adolescent cohort. Circulation？2006, 114(24), 2663–2670, doi:10.1161/CIRCULATIONAHA.106.624536. 17145992
[62]  Hardy, R.; Kuh, D.; Whincup, P.H.; Wadsworth, M.E. Age at puberty and adult blood pressure and body size in a British birth cohort study. J. Hypertens.？2006, 24(1), 59–66, doi:10.1097/01.hjh.0000198033.14848.93. 16331102
[63]  Seda, O.; Tremblay, J.; Gaudet, D.; Brunelle, P.L.; Gurau, A.; Merlo, E.; Pilote, L.; Orlov, S.N.; Boulva, F.; Petrovich, M.; Kotchen, T.A.; Cowley, A.W., Jr.; Hamet, P. Systematic, genome-wide, sex-specific linkage of cardiovascular traits in French Canadians. Hypertension？2008, 51(4), 1156–1162. 18259002

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133